CLINICAL_TRIALS
trial_result
· 2022-02-08
Clinical Trial Update: Semaglutide to Reduce Myocardial Injury in PATIents With COVID-19 [Phase 2]
Summary
Phase 2 trial update exploring semaglutide to reduce myocardial injury in patients with COVID-19.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Vladimír Džavík | Conditions: Covid19, Myocardial Injury | Phase 2 | Status: UNKNOWN